Breast cancer historical perspective
|
Breast Cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Breast cancer historical perspective On the Web |
|
American Roentgen Ray Society Images of Breast cancer historical perspective |
|
Risk calculators and risk factors for Breast cancer historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2] Soroush Seifirad, M.D.[3] Nehal Eid, M.D.[4]
Historical Perspective
This chapter summarizes the major discoveries and trials that transformed breast cancer care from a predominantly radical-surgery model into biology-directed, multimodal treatment. The milestones are presented for historical context; current screening, staging, and treatment recommendations belong in their dedicated microchapters.
The radical-surgery era
William Halsted described and popularized radical mastectomy in a landmark 1894 publication. The procedure became the dominant surgical model because breast cancer treatment was centered on progressively removing more local and regional tissue to achieve control of presumed contiguous spread.[1]
Systemic disease hypothesis and breast conservation
During the 1970s, the systemic disease hypothesis challenged the assumption that increasingly extensive local surgery could prevent distant relapse. The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 trial, initiated in 1971, found no significant survival advantage for radical mastectomy over less extensive surgical approaches at long-term follow-up.[2]
The introduction of adjuvant combination chemotherapy in the mid-1970s, notably cyclophosphamide, methotrexate, and fluorouracil (CMF), operationalized the systemic-disease hypothesis pharmacologically and established systemic therapy as a component of multimodal treatment.[1]
NSABP B-06 and the Milan quadrantectomy trial subsequently established that breast-conserving surgery followed by radiation could achieve survival outcomes comparable to mastectomy in appropriately selected early breast cancer.[3][4]
The 1990 NIH Consensus Development Conference helped establish breast conservation as an accepted treatment approach for early-stage disease. This marked a fundamental shift from maximal local surgery toward combined surgery, radiation, and systemic therapy.[5]
Parallel to de-escalation of breast surgery, axillary surgery was progressively minimized. Sentinel lymph node biopsy was introduced by Giuliano in 1994 and was subsequently validated in clinically node-negative disease, reducing the need for routine axillary lymph node dissection in many patients.[6][7]
Mammography and pathology milestones
The adoption of mammography as a population detection tool shifted breast cancer diagnosis toward earlier-stage disease and became a central milestone in modern breast cancer control. Detailed screening-trial chronology, screening intervals, and current society recommendations belong in the Screening microchapter.
The increasing use of estrogen receptor (ER), progesterone receptor (PR), and later HER2 testing changed breast cancer classification from anatomy alone to a combined anatomic, histologic, and biomarker-based framework. This development established the basis for subtype-directed systemic therapy.[8]
Endocrine therapy and hormonal prevention
Tamoxifen was synthesized in 1963 and became a landmark endocrine therapy and breast cancer prevention agent. The NSABP P-1 Breast Cancer Prevention Trial began accrual in 1992 and was reported in 1998. Five years of tamoxifen at 20 mg/day reduced invasive breast cancer incidence by 49% in women at increased risk; the preventive benefit was concentrated in estrogen receptor-positive tumors.[9]
Third-generation aromatase inhibitors later expanded endocrine-treatment options for postmenopausal patients and became an important subsequent milestone in the endocrine era.[10]
The Women's Health Initiative changed understanding of menopausal hormone therapy by demonstrating opposing, regimen-dependent effects. Estrogen-plus-progestin therapy significantly increased invasive breast cancer incidence, with a cumulative hazard ratio of 1.28 (95% confidence interval, 1.13–1.45), whereas estrogen-alone therapy in women with prior hysterectomy decreased incidence, with a hazard ratio of 0.78 (95% confidence interval, 0.65–0.93).[11][12]
HER2 discovery and trastuzumab
Recognition of HER2/ERBB2 amplification and overexpression introduced a clinically actionable molecular target. The association between HER2 amplification and breast cancer biology was reported in the 1980s, including a 1987 report identifying amplification in approximately 20–30% of breast cancers and associating it with poorer prognosis.[13]
Trastuzumab received FDA approval for metastatic HER2-positive breast cancer in 1998 and, following the 2005 joint analysis of the NSABP B-31 and NCCTG N9831 adjuvant trials, for adjuvant treatment of operable disease in 2006.[14][15]
The HER2 era demonstrated that a biomarker could define both prognosis and treatment sensitivity, accelerating the transition from histology-based treatment to molecularly targeted therapy.[16]
Genetic and genomic era
The hereditary basis of breast cancer became more clearly defined through the discovery of BRCA1 and BRCA2. BRCA1 was mapped to chromosome 17q in 1990 and positionally cloned in 1994; BRCA2 was identified in 1995.[17][18]
These discoveries connected inherited cancer susceptibility with DNA-repair biology and supported the later development of PARP-inhibitor therapy for selected patients.
The development of multigene assays, including the 21-gene recurrence score, introduced genomic recurrence biology into adjuvant decision-making. The TAILORx and RxPONDER trials subsequently refined the role of chemotherapy in selected hormone receptor-positive/HER2-negative disease.[19][20]
Immunotherapy and PARP-inhibitor era
More recent treatment history is defined by the integration of immune checkpoint inhibition and DNA-repair–targeted therapy into selected early breast cancers. KEYNOTE-522 established a landmark immunotherapy paradigm for high-risk TNBC, while OlympiA demonstrated the clinical importance of adjuvant olaparib for selected patients with germline BRCA1/2-associated, high-risk HER2-negative disease.[21][22]
These developments completed the transition from a predominantly anatomy-driven model to a framework integrating stage, histology, receptor status, inherited genetics, genomic assays, immune biology, and treatment response.
References
- ↑ 1.0 1.1 Downs-Canner S, Cody HS. Five decades of progress in surgical oncology: Breast. J Surg Oncol. 2022;126(5):852-859. doi:10.1002/jso.27035.
- ↑ Fisher B, Jeong JH, Anderson S, et al. Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation. N Engl J Med. 2002;347(8):567-575. doi:10.1056/NEJMoa020128.
- ↑ Fisher B, Anderson S, Bryant J, et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. N Engl J Med. 2002;347(16):1233-1241. doi:10.1056/NEJMoa022152.
- ↑ Veronesi U, Cascinelli N, Mariani L, et al. Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. N Engl J Med. 2002;347(16):1227-1232. doi:10.1056/NEJMoa020989.
- ↑ Lazovich D, Solomon CC, Thomas DB, Moe RE, White E. Breast Conservation Therapy in the United States Following the 1990 National Institutes of Health Consensus Development Conference on the Treatment of Patients With Early Stage Invasive Breast Carcinoma. Cancer. 1999;86(4):628-637.
- ↑ Owusu-Brackett N, Facer B, Quiroga D, et al. Axillary Management: How Much Is Too Much? Curr Oncol Rep. 2024;26(7):735-743. doi:10.1007/s11912-024-01539-0.
- ↑ Al-Hilli Z, Weiss A, Armani A, Boughey JC, Blair SL. Breast Cancer—The Catalyst of Contemporary Trials Design. J Surg Oncol. 2022;125(1):7-16. doi:10.1002/jso.26722.
- ↑ Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2.
- ↑ Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388. doi:10.1093/jnci/90.18.1371.
- ↑ Thomas NS, Scalzo RL, Wellberg EA. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nat Rev Endocrinol. 2024;20(1):16-26. doi:10.1038/s41574-023-00899-0.
- ↑ Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369-380. doi:10.1001/jama.2020.9482.
- ↑ Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748-1760. doi:10.1001/jama.2024.6542.
- ↑ Zhao H, Shen C, Laureano JJ, et al. Real-world neoadjuvant and adjuvant trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat. 2025;210(1):191-203. doi:10.1007/s10549-024-07552-y.
- ↑ Marra A, Chandarlapaty S, Modi S. Management of Patients With Advanced-Stage HER2-positive Breast Cancer: Current Evidence and Future Perspectives. Nat Rev Clin Oncol. 2024;21(3):185-202. doi:10.1038/s41571-023-00849-9.
- ↑ Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1673-1684. doi:10.1056/NEJMoa052122.
- ↑ Waks AG, Martínez-Sáez O, Tarantino P, et al. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat Rev Clin Oncol. 2024;21(11):818-832. doi:10.1038/s41571-024-00939-2.
- ↑ King MC. "The Race" to Clone BRCA1. Science. 2014;343(6178):1462-1465. doi:10.1126/science.1251900.
- ↑ Golmard L, Delnatte C, Laugé A, et al. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. Oncogene. 2016;35(10):1324-1327. doi:10.1038/onc.2015.181.
- ↑ Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710.
- ↑ Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021;385(25):2336-2347. doi:10.1056/NEJMoa2108873.
- ↑ Schmid P, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522). N Engl J Med. 2024.
- ↑ Tutt ANJ, et al. Adjuvant Olaparib for BRCA1/2-Mutated Breast Cancer (OlympiA). N Engl J Med. 2021.